Author

S. Parker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1

Frequent Co-Authors

A. Dukanovic· 1 shared A. Goodspeed· 1 shared A. Jean· 1 shared B. Bao· 1 shared B. Clemente· 1 shared C. B. Tilton· 1 shared C. Deiter· 1 shared C. Yau· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Dukanovic

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NPEPPS is a novel and druggable driver of platinum resistance

R. T. Jones, M. Scholtes, A. Goodspeed, M. M. Akbarzadeh, S. Mohapatra, L. E. Feldman, H. Vekony, A. Jean, C. B. Tilton, M. V. Orman, S. Romal, C. Deiter, T. W. Kan, N. Xander, S. Araki, , J. C. Costello

This study identifies NPEPPS as a driver of cisplatin resistance in bladder cancer and shows its inhibition can enhance cisplatin efficacy in preclinical models.

bioRxiv · Mar 4, 2021 · PreprintCancer Biology

A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice

R. M. de Alwis, E. S. Gan, S. Chen, Y. S. Leong, H. C. Tan, S. L. Zhang, C. Yau, D. Matsuda, E. Allen, P. Hartman, J. Park, M. Alayyoubi, H. Bhaskaran, A. Dukanovic, B. Bao, , E. E. Ooi

A single dose of the STARR-based SARS-CoV-2 vaccine LUNAR-COV19 induces protective adaptive immunity in mice, including strong antibody and CD8+ T cell responses, and full protection against viral challenge.

bioRxiv · Sep 3, 2020Immunology